Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Research

Intensity Therapeutics, a biotechnology company at the forefront of developing novel intratumoral cancer therapies, has successfully raised $6.6 million in gross proceeds through an At-the-Market (ATM) offering. This financial boost, achieved by selling 19,868,658 shares at an average price of $0.3323 per share, underscores the company's strategic approach to funding its groundbreaking research. With this capital infusion, Intensity Therapeutics is well-positioned to advance its clinical trials into the latter half of 2026, furthering its mission to revolutionize cancer treatment.

The company's proprietary technology, DfuseRx℠, is the foundation of its lead investigational product, INT230-6. This innovative therapy is designed for direct intratumoral injection, combining two potent anti-cancer agents with a diffusion enhancer to maximize tumor saturation and minimize systemic side effects. The success of INT230-6 in early clinical trials has demonstrated its potential to not only kill tumors but also to engage the immune system in fighting cancer, offering hope for patients with malignancies resistant to conventional treatments.

Intensity Therapeutics' recent financial achievement is a testament to the confidence investors have in its technology and approach. By leveraging the ATM offering mechanism, the company has managed to raise capital efficiently, with lower costs and minimal market disruption. This strategic financial move allows Intensity Therapeutics to continue its critical work in developing therapies that could transform the treatment landscape for various cancers, including those currently deemed untreatable.

For more information on Intensity Therapeutics and its pioneering cancer treatment research, visit https://www.intensitytherapeutics.com.